NIH Summit Delivers Recommendations to Transform Alzheimers Disease Research
The National Institutes of Health (NIH) has released recommendations that provide a framework for a bold and transformative Alzheimer’s disease research agenda. Developed at the recent Alzheimer’s Disease Research Summit 2015: Path to Treatment and Prevention, the highly anticipated recommendations provide the wider Alzheimer’s research community with a strategy for speeding the development of effective interventions for Alzheimer’s and related dementias. These recommendations call for a change in how the academic, biopharmaceutical and government sectors participating in Alzheimer’s research and therapy generate, share and use knowledge to propel the development of critically needed therapies.
“Alzheimer’s research is entering a new era in which creative approaches for detecting, measuring and analysing a wide range of biomedical data sets are leading to new insights about the causes and course of the disease,” said NIH Director Francis S. Collins. “In these times of significant fiscal constraints, we need to work smarter, faster and more collaboratively. These recommendations underscore the importance of data sharing and multidisciplinary partnerships to a research community that looks to the NIH for guidance on the way forward.”
Over 60 leading Alzheimer’s and chronic disease experts from academia, industry, non-profit organizations and advocacy groups joined to develop the research recommendations. Convened by the National Institute on Aging (NIA) at NIH and the US. Department of Health and Human Services, with support from the Foundation for NIH, the 9–10 February 2015, meeting drew 500 participants onsite, with another 500 participating via videocast.
The recommendations, which are to be considered by the National Advisory Council on Aging at its meeting on 12 and 13 May, outline new scientific approaches to address critical knowledge gaps and propose ways to harness emerging technologies to accelerate treatments for people at all stages of the disease. They also identify infrastructure and partnerships necessary to successfully implement the new research agenda and strategies to empower patients and engage citizens.
Overarching Alzheimer’s disease research themes include
• Understand all aspects of healthy brain ageing and cognitive resilience to inform strategies for Alzheimer’s disease prevention.
• Expand integrative, data-driven research approaches such as systems biology and systems pharmacology.
• Develop computational tools and infrastructure to enable storage, integration and analysis of large-scale biological and other patient-relevant data.
• Leverage the use of wearable sensors and other mobile health technologies to inform discovery science, as well as research on Alzheimer’s disease care.
• Support and enable Open Science in basic, translational and clinical research.
• Change the academic, publishing and funding incentives to promote collaborative, transparent and reproducible research.
• Invest in the development of a new translational and data science workforce.
• Engage citizens, caregivers and patients as equal partners in Alzheimer’s disease research.
“Determining the best path for progress in Alzheimer’s disease research has been as challenging and complicated as the disorder itself,” said NIA Director Richard J. Hodes. “These recommendations support a research framework that empowers all stakeholders — including those with the disease or at risk for developing it — to engage in the vital effort to find treatments.”
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.